File: bbe25bvw3_pub_fr.pdfTrial reference: Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia BDoc type: Information for the public